Podcast Episodes
Back to Search
BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy
Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for, and how Hansa …
1 year, 2 months ago
BIO International 2025: Oppenheimer's Head of Healthcare Investment Banking, Michael Margolis, discusses biotech sentiment, M&A, and what it is like to raise money today
He describes how sentiment and the M&A environment have been improving, as well as some areas of the financing market. However, he cautions that it i…
1 year, 2 months ago
BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs
He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short half-life. Plus,…
1 year, 2 months ago
BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions
He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs. Nkarta will …
1 year, 2 months ago
BIO International 2025: Germany's Aicuris, a company that focuses on helping immunocompromised patients, has breakthrough therapy designation for its HSV treatment that is in a pivotal
CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS), partnered with …
1 year, 2 months ago
BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection …
1 year, 2 months ago
BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next
He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for th…
1 year, 2 months ago
BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues
He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors. Plus, his ta…
1 year, 3 months ago
BIO International 2025: Ocugen CEO Shankar Musunuri discusses the company's gene therapy platform for eye conditions - one of which is already in a pivotal, with another to start
He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA today), and geog…
1 year, 3 months ago
EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T
He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market, Carvykti. Plus …
1 year, 3 months ago